	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	328.85	427.60	465.93	513.08	630.96	759.88	904.09	942.10
Cost of Operating Revenue	228.93	298.90	325.97	350.71	425.77	521.45	616.27	610.73
Gross Profit	99.92	128.70	139.96	162.37	205.19	238.43	287.82	331.36
Gross Margin	30.4	30.1	30.0	31.6	32.5	31.4	31.8	35.2
Total Operating Expenses	296.64	384.19	425.65	465.21	566.23	693.38	830.09	867.70
Operating Profit	32.21	43.41	40.28	47.87	64.73	66.49	74.00	74.40
Operating Margin	9.8	10.2	8.6	9.3	10.3	8.8	8.2	7.9
Financing Income/(Expense) - Net	-0.97	6.70	3.35	3.08	1.13	-2.35	-1.82	-5.42
Profit before Taxes	24.67	21.74	45.56	57.04	77.09	79.76	86.98	86.66
Income Taxes	8.46	6.17	7.48	14.41	18.90	18.76	20.52	20.21
Profit after Tax	16.21	15.83	38.09	42.63	58.19	60.99	66.46	66.45
PAT Margin	4.9	3.7	8.2	8.3	9.2	8.0	7.4	7.1
EPS - Basic - ex Extraordinary Items	7.44	7.26	18.58	19.70	27.97	29.19	31.60	31.56
EPS - Diluted - ex Extraordinary Items	7.44	7.26	18.58	19.70	27.88	28.87	31.15	31.16
EBIT	32.21	43.41	40.28	47.87	64.73	66.49	74.00	74.40
EBITDA	41.50	56.38	52.42	60.23	78.17	94.48	104.74	104.90
EBITDA Margin	12.6	13.2	11.3	11.7	12.4	12.4	11.6	11.1

Balance Sheet

Abridged

Understanding Balance Sheet

Windlas Biotech Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	168.03	194.31	381.65	353.54	431.29	525.13	626.85
Long-Term Investments	-	-	2.56	5.82	1.98	0.97	1.75
Property Plant & Equipment - Net	69.71	95.50	98.31	122.70	180.29	221.93	266.01
Total Non-Current Assets	170.46	101.81	109.36	175.44	194.92	235.32	280.50
Total Assets	338.49	296.12	491.01	528.98	626.21	760.45	907.35
Total Current Liabilities	125.29	93.42	93.99	121.24	171.75	249.44	320.93
Long Term Debt	2.25	1.35	0.44	3.13	2.02	2.25	2.15
Total Non-Current Liabilities	3.54	3.58	2.25	5.46	4.52	5.24	5.58
Total Liabilities	128.83	97.00	96.23	126.70	176.27	254.68	326.51
Total Shareholders' Equity	209.66	199.12	394.78	402.27	449.94	505.77	580.84
Minority Interest	-	-	-	-	-	-	-
Total Equity	209.66	199.12	394.78	402.27	449.94	505.77	580.84
Total Liabilities & Equity	338.49	296.12	491.01	528.98	626.21	760.45	907.35

Cash Flow

Abridged

Understanding Cash Flow Statement

Windlas Biotech Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	26.85	51.33	48.09	58.98	66.14	75.19	105.91
Working Capital - Increase/(Decrease)	-3.57	-39.58	-37.81	5.75	43.45	-9.76	-4.48
Net CF from Operating Activities	23.28	11.75	10.28	64.73	109.59	65.43	101.43
Capital Expenditures - Net	15.18	5.83	14.69	69.98	37.64	52.00	67.66
Net CF from Investing Activities	-15.15	-21.86	-157.14	-18.66	-93.81	-75.69	-93.11
Dividends Paid - Cash - Total	-	-	-	7.63	8.30	11.50	12.16
Stock - Issuance/(Retirement) - Net	-	-	165.00	-27.19	-4.02	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	-2.91	3.42	-25.71	-6.99	-1.86	12.46	-0.09
Net Cash Flow from Financing Activities	-2.91	2.14	131.50	-42.95	-14.18	5.40	-8.21
Free Cash Flow to Equity	5.19	9.33	-30.13	-12.25	70.09	25.90	33.67
Free Operating CF net dividend	8.08	5.90	-4.53	-13.79	63.61	1.74	21.61
Free Operating CF	8.08	5.90	-4.53	-6.16	71.91	13.24	33.77

Business Segment Analysis

FY End:

Mar 26

Windlas Biotech Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceutical (100.0%)₹ 67.66 Cr

Revenue / Sales

Pharmaceutical (100.0%)₹ 904.09 Cr

Assets

Pharmaceutical (100.0%)₹ 907.35 Cr

Operating Income

Pharmaceutical (100.0%)₹ 74.00 Cr

Regional Segment Analysis

FY End:

Mar 22

Windlas Biotech Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (100.0%)₹ 465.93 Cr

Assets

India (100.0%)₹ 491.01 Cr

Historical Segment Analysis

Track how Windlas Biotech Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Pharmaceutical	15	6	15	71	38	52	68

Frequently Asked Questions

What is the revenue of Windlas Biotech Ltd.?

The latest trailing twelve month revenue of Windlas Biotech Ltd. is ₹ 942.10 Cr, reflecting a 1-year growth of 18.53% and a 3-year CAGR of 20.54%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Windlas Biotech Ltd.?

The latest trailing twelve month net profit (PAT) of Windlas Biotech Ltd. is ₹ 66.44 Cr, with a 3-year earnings CAGR of 14.07%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Windlas Biotech Ltd.?

The trailing twelve month EBITDA of Windlas Biotech Ltd. is approximately ₹ 74.40 Cr (based on an operating margin of 7.90%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Windlas Biotech Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Windlas Biotech Ltd. is 31.16. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Windlas Biotech Ltd.?

The debt-to-equity ratio of Windlas Biotech Ltd. stands at 0.06. The interest coverage ratio is 13.73x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Windlas Biotech Ltd.?

The estimated book value per share of Windlas Biotech Ltd. is 281.47 (derived from a P/B ratio of 3.10 and market price of ₹ 872.70), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Windlas Biotech Ltd.?

The trailing twelve month operating cash flow of Windlas Biotech Ltd. is ₹ 101.43 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Windlas Biotech Ltd. report consolidated or standalone financials?

Windlas Biotech Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.